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Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of referral to liver
clinics, and its progressive form, non-alcoholic steatohepatitis (NASH), can lead to cirrho-
sis and end-stage liver disease. The main risk factors for NAFLD/NASH are the metabolic
abnormalities commonly observed in metabolic syndrome: insulin resistance, visceral
obesity, dyslipidemia and altered adipokine profile. At present, the causes of progression
from NAFLD to NASH remain poorly defined, and research in this area has been limited
by the availability of suitable animal models of this disease. In the past, the main models
used to investigate the pathogenesis of steatohepatitis have either failed to reproduce the
full spectrum of liver pathology that characterizes human NASH, or the liver pathology has
developed in a metabolic context that is not representative of the human condition. In the
last few years, a number of models have been described in which the full spectrum of liver
pathology develops in an appropriate metabolic context. In general, the underlying cause of
metabolic defects in these models is chronic caloric overconsumption, also known as
overnutrition. Overnutrition has been achieved in a number of different ways, including
forced feeding, administration of high-fat diets, the use of genetically hyperphagic animals,
or a combination of these approaches. The purpose of the present review is to critique the
liver pathology and metabolic abnormalities present in currently available animal models of
NASH, with particular focus on models described in approximately the last 5 years.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is increasingly preva-
lent and strongly associated with obesity, diabetes and the meta-
bolic syndrome. In 1980, the term non-alcoholic steatohepatitis
(NASH) was first used by Ludwig et al.1 to describe, among non-
drinkers, the liver pathology (steatohepatitis) previously thought to
be uniquely associated with alcoholic liver disease. NAFLD is the
preferred term to NASH when the pathology has not been defined,
because the same metabolic determinants are associated with a
spectrum of pathology from bland steatosis through steatohepatitis
to cirrhosis and, possibly, hepatocellular carcinoma. NAFLD/
NASH was initially thought to be a disease of the Western world,
but it is now clear that the prevalence is very high in many regions,
from the USA to South America, the Middle East, Europe, Asia
and Australia.2,3 The major risk factors are overnutrition and its
resultant disorders: obesity, insulin resistance, glucose intolerance
and dyslipidemia.4
Clinical research into mechanisms of steatohepatitis develop-
ment and progression are constrained by ethical considerations,
particularly with respect to obtaining liver and other tissue, and
by limited ability to delineate cause and effect from complex,
interactive disease pathogenic pathways. It is therefore attractive
experimentally to use animal models. However, for the informa-
tion derived from these models to have clear relevance to human
liver disease, the models need to accurately reflect not only the
liver pathology of NASH, but also the context within which it
develops. There are a variety of genetic and dietary models of
NAFLD, but few show progression to the inflammatory condition
of steatohepatitis. Conversely, the methionine- and choline-
deficient (MCD) model does show steatohepatitis and has been
widely used, but there is understandable controversy over its valid-
ity.5 It is fair to say that the popularity of the MCD model stemmed
from a lack of alternative models which recapitulate the liver
pathology of human NASH. It is now reasonable considered that
the weight loss and whole-body insulin sensitivity associated with
MCD feeding (despite demonstrated impairment of hepatic insulin
receptor signaling)6 limits the extrapolation of data from this
model to NASH.7,8 In recent years, several new animal models
have been described. These appear promising for researchers
investigating one of the key issues in NASH; not so much why
steatosis occurs, but what causes the transition from bland steato-
sis to the inflammatory and progressive fibrosing condition of
steatohepatitis.
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NASH: What we know and what we
don’t know
Histopathology
While diagnostic criteria for pathological description of human
NASH continue to evolve, current concepts center on steatosis,
inflammation with liver cell injury, and the distinctive pattern of
pericellular fibrosis.9 By using these criteria, steatohepatitis can be
separated from steatosis conceptually, but in practice, however,
NASH may be difficult to distinguish from simple steatosis with
minor inflammation if one uses oversimplified criteria.10 In
humans, ballooning of hepatocytes is a morphological manifesta-
tion of liver cell injury. It is thought to result from accumulation of
intracellular fluid and/or other forms of toxic cell injury. Balloon-
ing (or cellular) degeneration is characterized by swelling of
hepatocytes which show rarefied cytoplasm (Fig. 1c, inset).11 A
frequently quoted clinicopathological study conducted by Mat-
teoni et al. suggested that hepatocytic ballooning is a key feature
that distinguished progressive NASH from the less progressive
forms of NAFLD.12 It has also been shown that patients whose
livers show ballooning degeneration with fat accumulation and
Mallory hyaline or fibrosis have a higher rate of developing cir-
rhosis and liver-related death, compared with patients whose livers
show fat accumulation alone or with lobular inflammation only.4
Furthermore, a clinicopathological study based on a blinded
review of entry biopsy specimens for a treatment trial showed that
hepatocytic ballooning was associated with higher serum choles-
terol levels.13 There was also a trend toward the presence of bal-
looning in biopsy specimens from patients with abnormal
glycemic control, greater insulin resistance, and increased serum
markers of necroinflammation.13
Using multiple regression analysis, it has been shown that the
diagnosis of NASH is not dependent on a single histological
feature. Instead, it involves assessment of multiple independent
features.14 Using multivariate analysis, the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK)-sponsored
NASH Clinical Research Network study identified several features
that are significantly associated with a diagnosis of NASH; these
include lobular inflammation, ballooning degeneration, fibrosis,
and steatosis.15 The aforementioned histological changes are there-
fore now considered to be the most helpful features to establish a
diagnosis of NASH, and they comprise a common set of minimal
criteria for this diagnosis.16 It is noted that minor differences in the
predominance of each of these features may occur under some
circumstances. For instance, ballooning is less prominent in chil-
dren, in whom periportal fibrosis may be more conspicuous than
pericentral fibrosis,15,17 whereas livers showing cirrhosis may
exhibit little or no steatosis.16 The extent to which these criteria can
be used to define animal models of NASH remains unclear, but in
the present review we will comment on both similarities and sub-
stantial differences.
Pathogenesis
The most reproducible risk factors for NASH are abdominal
(central or visceral) obesity, insulin resistance, fasting hypergly-
cemia and hypertriglyceridemia.4 The severity of NAFLD corre-
lates with the number of criteria met for metabolic syndrome; in
two large series, >85% of patients with NASH had established
metabolic syndrome.18,19 More recently, it has become clear that
fatty liver may precede the onset of metabolic syndrome and its
complications.20,21 In light of these observations, it is appropriate
that NAFLD, and particularly NASH, is increasingly referred to as
the hepatic manifestation of metabolic syndrome.22
A key feature of metabolic syndrome is the profile of changes in
serum levels of adipokines (increased leptin and tumor necrosis
factor-alpha [TNF-a], decreased adiponectin). It is therefore not
surprising that the same alterations of serum adipokine profile are
prevalent in NAFLD. Importantly, there have been several inde-
pendent reports that serum adiponectin levels correlate inversely
with NASH severity.23–25 Insulin resistance likely plays a patho-
genic role in the development and progression of NAFLD, but the
complex relationship between hepatic steatosis and insulin sensi-
tivity makes it difficult to assign cause and effect.26 Obesity, but
more particularly, increased intra-abdominal (visceral) adipose
tissue (VAT) mass is almost universal in NASH.27 Similar to
insulin resistance, this likely contributes to the pathogenesis of
fatty liver disease.26 For example, enlarged visceral adipose stores
are associated with an increased flux of free fatty acids from VAT
to liver via the portal circulation, impaired insulin sensitivity,
increased levels of pro-inflammatory cytokines such as TNF-a and
interleukin (IL)-6, and decreased levels of adiponectin.28–31
The potential causes of steatosis in NAFLD are generally under-
stood and have been reviewed elsewhere.26,32,33 In contrast, the
cellular mechanisms involved in inflammatory cell recruitment,
hepatocyte injury and fibrogenesis are not well understood, and
have been the subject of conjecture and controversy. Roles for
oxidant stress, mitochondrial injury, pro-inflammatory cytokines
and lipotoxicity have all been suggested.34 Clearly, more research
is required to determine the contribution of these factors, and their
potential interaction, to steatohepatitis pathogenesis. Such mecha-
nistic understanding of hepatocellular injury and inflammatory
recruitment in metabolic liver disease is important for the devel-
opment of targeted therapeutic interventions. In order to progress
this understanding, animal models that accurately reflect not only
the liver pathology of human NASH, but also the metabolic milieu
in which it develops are essential.
Animal models of NASH: What are we
looking for?
The importance of animal models and knowledge derived from
earlier studies have been reviewed by others over the last few
years.35–37 The purpose of the present review is to focus more
particularly on those models with appropriate pathology for
NASH, and with the same metabolic setting of overnutrition
rather than nutritional depletion or genetic manipulation. As men-
tioned, the two key criteria that animal models of NASH should
fulfil are: (i) that the pathological pattern of liver injury reflects
that which defines human steatohepatitis; and (ii) the model reca-
pitulates the context within which human NASH develops. Short-
comings in either the liver pathology or metabolic context of
experimental NASH make it difficult to translate research from
the laboratory bench into the clinical setting. Explicitly, an
animal model of NASH must have liver pathology that features
steatosis, inflammation, liver cell injury (ballooning of hepato-
cytes) and progression to fibrosis, particularly the specific
perivenular/ pericellular (chicken wire) pattern of fibrosis
Animal models of steatohepatitis CZ Larter and MM Yeh
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Figure 1 Liver histology of obese high-fat-fed foz/foz mice shows fibrosing steatohepatitis. (a) Liver of the wild-type mice fed with a high-fat diet
for 300 days showed no significant histological changes including no significant steatosis or inflammation (H&E stain, 40¥ magnification). (b) foz/foz
Mice fed with a normal diet for 300 days showed mild mixed micro- and macrovesicular steatosis, predominantly macrovesicular, in a zone 3
distribution pattern (H&E stain, 40¥ magnification). (c) foz/foz Mice fed with a high-fat diet for 300 days showed more extensive steatosis, there were
ballooned hepatocytes (arrows, H&E stain, 100¥ magnification). Inset: Ballooned hepatocytes in a background of steatosis in human non-alcoholic
steatohepatitis (arrows, H&E stain, 600¥ magnification). (d) There were also many foci of inflammatory cells, composed predominantly of neutrophils
and mononuclear cells, in the hepatic lobules in foz/foz mice fed with a high-fat diet for 300 days (arrows, H&E stain, 100¥ magnification). (e) Sirius
red stain shows perivenular and pericellular fibrosis in foz/foz mice fed with a high-fat diet for 300 days (arrows, Sirius red stain, 100¥ magnification).
CV, central vein. (f) foz/foz Mice are severely obese in comparison to wild-type controls (mice depicted are 6 months of age).
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commonly seen in adult NASH. Also, the model should exhibit
metabolic abnormalities such as obesity, insulin resistance,
fasting hyperglycemia, dyslipidemia and altered adipokine
profile. Preferably, animals will be both obese and insulin resis-
tant. Furthermore, the more of the above-mentioned metabolic
criteria that are met, the more intrinsically useful the model
becomes as it will enable examination of the separate and inter-
active impacts of individual metabolic abnormalities on liver
pathology. Given the complexities of human behavior and
biology, it is also critical that steatohepatitis researchers do not
study the liver in isolation: appetite regulation, physical activity,
food choices, genetics and humoral determinants of body com-
position, metabolic regulation, and inflammation in extrahepatic
tissues may each play a role in NASH pathogenesis.
Animal models of steatohepatitis
Genetic models
Genetic models of obesity-related liver injury can be broadly clas-
sified into two groups: (i) those in which steatohepatitis develops
with no or minimal features of metabolic syndrome; and (ii) those
in which steatosis develops in the context of obesity and features
of metabolic syndrome, but where there is only minor and non-
progressive liver injury. Many of these models have been reviewed
previously,35,36 so only a brief overview will be provided here. The
first category includes mice nullizygous for acyl-CoA oxidase
(ACOX), methionine adenosyltransferase (MAT)-1A (MATO
mice), and those with liver-specific pten deletion. ACOX is the
first and rate-limiting step of peroxisomal b-oxidation of long
chain fatty acids. Deletion of this gene leads to severe steatosis and
inflammatory infiltration of the liver with hepatocyte apoptosis,
but animals are growth retarded and do not exhibit features of
metabolic syndrome.38 Further, at 6–8 months of age, ACOX null
mice become resistant to steatosis following a process of liver
regeneration associated with peroxisome proliferator-activated
receptor (PPAR)a induction. This regeneration limits the utility of
this model for studying the pathogenesis of steatohepatitis, as
disease progression thereafter is different from human NASH.
Steatohepatitis develops in chow-fed MATO mice at approxi-
mately 8 months of age.39 MAT-1A is involved in the synthesis of
phosphatidylcholine, a phospholipid required for hepatic triglyc-
eride export as very low-density lipoprotein (VLDL). Steatohepa-
titis in MATO mice is associated with marked oxidant stress,40 a
candidate mediator of inflammatory recruitment, and hepatocar-
cinogenesis, a later stage in the evolution of resultant liver disease.
Although MATO mice are hyperglycemic, they have normal
insulin levels and appear to not develop other features of metabolic
syndrome.39 pten is a multifunctional phosphatase and tumor sup-
pressor. Steatohepatitis develops in mice lacking hepatocyte pten
expression, but mice actually have improved insulin sensitivity and
low serum insulin levels.41 Like MATO mice, liver-specific pten
deletion is also associated with hepatocarcinogenesis; the time-
frame of development is similar to steatohepatitis. It is therefore
difficult to delineate effects of steatohepatitis from tumorigenesis
in this model.
In contrast to the above models, mice lacking either leptin
(ob/ob) or the long form of the leptin receptor (db/db) are obese,
hyperphagic, insulin resistant and develop hepatic steatosis and
type 2 diabetes.42 Although the metabolic abnormalities resemble
NAFLD, spontaneous development of steatohepatitis is not a
feature of these strains, although older males do show some mono-
nuclear cell infiltration of liver and elevation of serum alanine
aminotransferase (ALT). Another feature of ob/ob mice is that they
are protected against fibrosis,43 a phenomenon which led to the
characterization of leptin as an essential mediator of hepatic
fibrogenesis.43,44 Two methods are commonly used to induce
steatohepatitis in these obese mice, either a second insult, such
as low-dose lipopolysaccharide,45 or administration of the
methionine- and choline-deficient diet (see following section).
Another genetic model of steatosis in association with insulin
resistance is the sterol regulator element binding protein
(SREBP)-1c transgenic mouse. In these animals, SREBP1c, a
lipogenic transcription factor, is overexpressed in adipose tissue.
This creates a model of congenital lipodystrophy in which severe
insulin resistance and diabetes develop secondary to impaired
adipose differentiation.46 The restriction in adipose mass causes
hepatic lipid accumulation, with marked steatosis present from as
young as 8 days of age. When fed standard rodent chow, steatosis,
lobular inflammation, and perivenular and pericellular fibrosis
were observed in SREBP-1c transgenic mice by 20 weeks
(Table 1).47 Ballooned hepatocytes and Mallory bodies were
described, which are important histological features for the diag-
nosis of steatohepatitis. However, it is unclear whether the mor-
phology depicted is representative. At 20 weeks of age, serum
leptin and adiponectin levels were decreased, whereas serum trig-
lyceride and cholesterol levels were increased. ALT levels were
not increased, although serum aspartate aminotransferase (AST)
levels were increased. Overall, this model appears to be well suited
for the study of lipodystrophy-associated steatohepatitis, in which
low serum leptin levels are also found, but note that serum leptin
levels are usually increased with obesity and in NAFLD/NASH.
However, the fact that these mice exhibit decreased adipose mass
limits their applicability to the broader field of NAFLD/NASH
research, because in obesity-related NASH, the adipose tissue is a
storage compartment which is likely to contribute to perturbations
of whole-body lipid homeostasis.
Methionine- and choline-deficient
model
Methionine and choline deficiency rapidly induces steatohepatitis
in rodents. In contrast to choline-only deficiency, MCD-fed mice
exhibit a liver phenotype that is strikingly similar to the MATO
mouse, in which intrahepatic methionine deficiency likewise
occurs.39 Triglycerides and lipoperoxides accumulate, and while
these changes are variable, levels usually become significantly
increased compared to appropriate dietary controls after 2–5 days
of MCD feeding. After 5 days of MCD feeding, serum ALT levels
are consistently increased, although generally not significantly so
until day 10.48 After 3 weeks of MCD feeding, steatohepatitis is
well developed, and by 8–10 weeks pericellular and perisinusoidal
fibrosis are present.7,49 After 10 weeks of dietary feeding, there is
extensive macrovesicular steatosis in all zones except the peripor-
tal region, together with multiple foci of necroinflammation in the
liver. The hepatic inflammatory infiltrate includes lymphocytes
Animal models of steatohepatitis CZ Larter and MM Yeh
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and neutrophils. Pervivenular and pericellular fibrosis, the
so-called chicken-wire fibrosis typically seen in human NASH,
also readily develops. One recent article reported severe fibrosis at
4 weeks,50 which differs from the extensive experience in the
authors’ laboratory and elsewhere, which finds no fibrosis at week
3 and minimal increase in collagen at week 5 of MCD dietary
feeding. Furthermore, the depicted fibrosis did not show the
typical chicken-wire pattern observed in MCD-induced steato-
hepatitis. Administration of the MCD diet for 3 weeks leads to
steatosis, inflammation and ballooning degeneration of hepato-
cytes, culminating in NAFLD activity scores significantly higher
than in control-fed mice.
The major disadvantage of the MCD model is that it is associ-
ated with significant weight loss, often >20% of bodyweight after
3 weeks, low serum leptin and peripheral insulin sensitivity
(Table 1).8 The severe atrophy of adipose tissue in MCD-fed mice
suggests that steatohepatitis in this model may reflect that associ-
ated with lipodystrophy rather than metabolic syndrome.51 Further,
the metabolic profile of MCD-fed mice is generally the converse of
human NASH; serum insulin and leptin levels are decreased,
fasting blood glucose levels are low, animals are peripherally
insulin sensitive, and serum adiponectin levels are unchanged or
increased.52–55
Attempts to overcome these metabolic obstacles include giving
the MCD diet to genetically obese mice. MCD-fed ob/ob mice
develop steatohepatitis, but exhibit marked weight loss and liver
disease does not progress to fibrosis, presumably due to leptin
deficiency.56 Fibrosis does develop in db/db mice,56 but despite
some reports of persistent obesity and insulin resistance,56 other
studies clearly demonstrate significant reductions in bodyweight57
and also marked decreases in serum insulin and glucose levels.58
As only modest weight loss is required to improve the metabolic
phenotype,59 it is evident that use of db/db mice for administration
of the MCD diet does not completely overcome the limitations of
this model of nutritional depletion. The concurrent weight loss and
improvements in insulin sensitivity and glucose metabolism would
be expected to obscure any effect of these important metabolic
perturbations on steatohepatitis development.
Steatohepatitis in atherogenic models
Non-alcoholic steatohepatitis is associated with increased risk of
cardiovascular disease, even independently of its association with
metabolic syndrome,20 and alterations in blood cholesterol as well
as triglyceride levels are common. Previously, it has been observed
that genetic susceptibility to atherosclerosis or feeding an athero-
genic diet, typically containing cholate and increased cholesterol
and/or fat content, leads to hepatic steatosis and liver injury.
Recent studies have specifically addressed whether giving an
atherogenic diet to genetically susceptible or wild-type mice
induces steatohepatitis. Apolipoprotein E (ApoE) is involved in
hepatic lipoprotein clearance from blood. Both ApoE2 knock-in
and ApoE null mice develop marked hyperlipoproteinemia when
given an atherogenic diet (Table 2).60,61 ApoE2 knock-in mice
express a mutant human form of ApoE which has reduced binding
affinity for lipoprotein lipase, thereby leading to decreased lipo-
protein clearance. When fed a ‘Western diet’ with 21% fat and
0.2% cholesterol by weight for 3 weeks, ApoE2 knock-in mice
exhibited marked elevations in serum cholesterol and triglyceride
levels, as well as hepatic abnormalities.60 Although steatosis devel-
oped early, the extent was very mild, and hepatic triglyceride
content was not reported. A striking observation was the early
appearance of macrophages in the liver, even preceding the emer-
gence of steatosis. Kupffer cell numbers increased over time,
together with other inflammatory cells, to form larger aggregates.
Conversely, fibrate treatment (to stimulate PPARa) reduced the
number of macrophages. Together, these data indicate that an
increase in hepatic macrophage numbers is an early event during
the development of steatohepatitis in this model, and that this can
be mitigated by PPAR-a activation. Development of fibrosis was
described in this model, but the only hard data were upregulation
of collagen synthesis genes; the morphological pattern of fibrosis
was not depicted.60
In a similar study, ApoE null mice were fed a 20% palm or olive
oil diet with modest cholesterol (0.1%) for up to 24 weeks. Con-
sequently, animals developed macrovesicular steatosis and inflam-
matory foci consisting of mononuclear cells and neutrophils.61
Notably, there were again abnormally high numbers of macroph-
ages in the hepatic parenchyma. While the former two findings are
common observations in non-alcoholic models of steatohepatitis,
prominent macrophages are not typical.61 Few data were provided
as to the metabolic phenotype of high-fat-fed ApoE null mice,
although the expected increases in plasma cholesterol were
observed. Other reports of high-fat-fed ApoE null mice indicate
that they are actually protected against diet-induced obesity and
maintain peripheral glucose tolerance. A likely explanation is
decreased lipid delivery to tissues such as muscle and adipose.62
Thus, whereas published data are insufficient to fully assess the
validity of this model for the study of NAFLD pathogenesis, it
appears likely that the similarities with human NASH are limited
to the association with dyslipidemia and some (but not all)
common histopathological features.
In a similar approach using wild-type mice, giving a high-fat
atherogenic (Ath+HF; 60% fat, 1.25% cholesterol and 0.5%
cholate by weight) diet for up to 24 weeks appeared to induce
steatohepatitis (Table 1).63 Pathological features included steato-
sis, inflammation, fibrosis and, in addition, ballooned hepatocytes;
the latter is a critical histological component for the diagnosis of
human NASH and has been noted in very few animal models. The
addition of a high-fat component to the Ath diet accelerated the
development of steatosis, inflammation, fibrosis, and ballooned
hepatocytes. It appears the pattern of fibrosis is perivenular and
pericellular, which is similar to human NASH. However, there are
a number of features in this model that raise concern over the
validity of its use to study the pathogenesis of steatohepatitis. First,
hepatic triglyceride content decreased with time, as did serum ALT
levels in Ath+HF-fed mice. Second, mice fed the Ath+HF diet
were smaller than control mice and had smaller epididymal
adipose pads. Further, insulin sensitivity and glucose tolerance
were similar between Ath+HF and control-fed mice, albeit there
was some evidence of hepatic insulin resistance. Last, and of most
concern, was the formulation of the diets used. Instead of increas-
ing dietary fat content at the expense of carbohydrate content,
additional fat, cholesterol and cholate were added to a normal
rodent diet. This approach resulted in a significant reduction in
dietary protein content (from 22% to 8.6% by weight), which is
below the maintenance requirements of mice.64 There was also a
Animal models of steatohepatitis CZ Larter and MM Yeh
6 Journal of Gastroenterology and Hepatology (2008) © 2008 The Authors
Journal compilation © 2008 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
JOBNAME: No Job Name PAGE: 7 SESS: 9 OUTPUT: Tue Jul 15 12:48:46 2008 SUM: 69CDBC20
/v2503/blackwell/journals/jgh_v23_i8/jgh_5543
Ta
b
le
2
A
ni
m
al
m
od
el
s
of
st
ea
to
he
pa
tit
is
sh
ow
in
g
ap
pr
op
ria
te
m
et
ab
ol
ic
co
nt
ex
t,
bu
t
lim
ite
d
ch
ar
ac
te
riz
at
io
n
pa
th
ol
og
y
M
od
el
Ty
pe
of
m
od
el
M
et
ab
ol
ic
ph
en
ot
yp
e
Li
ve
r
hi
st
ol
og
y
O
be
si
ty
In
su
lin
re
si
st
an
ce
A
bn
or
m
al
ad
ip
ok
in
es
D
ys
lip
id
em
ia
S
te
at
os
is
In
fla
m
m
at
io
n
H
ep
at
oc
yt
e
in
ju
ry
Fi
br
os
is
ob
/o
b
m
ic
e
re
vi
ew
ed
in
32
,3
3
G
en
et
ic
le
pt
in
de
fic
ie
nt
Ye
s
↑
W
ei
gh
t
↑A
di
po
si
ty
Ye
s
↑In
su
lin
↑G
lu
co
se
Ye
s
↑T
N
Fa
↓A
di
po
ne
ct
in
Ye
s
↑T
rig
ly
ce
rid
e
↑C
ho
le
st
er
ol
↑F
FA
Ye
s
A
ge
-r
el
at
ed
in
fla
m
m
at
io
n
in
m
al
es
N
ot
de
sc
rib
ed
,
bu
t
re
po
rt
s
of
A
LT
el
ev
at
io
n
N
o
R
es
is
ta
nt
to
fib
ro
si
s
db
/d
b
m
ic
e
re
vi
ew
ed
in
32
,3
3
G
en
et
ic
Le
pt
in
re
ce
pt
or
de
fic
ie
nt
Ye
s
↑W
ei
gh
t
↑A
di
po
si
ty
Ye
s
↑In
su
lin
↑G
lu
co
se
Ye
s
↑T
N
F-
a
↓A
di
po
ne
ct
in
Ye
s
↑T
rig
ly
ce
rid
e
↑C
ho
le
st
er
ol
↑F
FA
Ye
s
N
ot
de
sc
rib
ed
N
ot
de
sc
rib
ed
N
o
D
oe
s
no
t
de
ve
lo
p
sp
on
ta
ne
ou
sl
y
H
ig
h-
fa
t-
fe
d
A
po
E
2
kn
oc
k-
in
m
ic
e6
0
D
ie
ta
ry
an
d
ge
ne
tic
N
ot
de
sc
rib
ed
N
o
N
or
m
al
gl
uc
os
e
N
ot
de
sc
rib
ed
Ye
s
↑T
rig
ly
ce
rid
e
↑C
ho
le
st
er
ol
Ye
s
M
ild
Ye
s
H
ig
h
nu
m
be
r
of
m
ac
ro
ph
ag
es
N
ot
de
sc
rib
ed
U
pr
eg
ul
at
io
n
of
co
lla
ge
n
sy
nt
he
si
s
ge
ne
s
H
ig
h
fa
t-
fe
d
A
po
E
nu
ll
m
ic
e6
1
D
ie
ta
ry
an
d
ge
ne
tic
N
ot
de
sc
rib
ed
N
ot
de
sc
rib
ed
O
th
er
re
po
rt
s
in
di
ca
te
gl
uc
os
e
to
le
ra
nc
e
N
ot
de
sc
rib
ed
Ye
s
↑C
ho
le
st
er
ol
Ye
s
M
ac
ro
ve
si
cu
la
r
Ye
s
H
ig
h
nu
m
be
r
of
m
ac
ro
ph
ag
es
N
ot
de
sc
rib
ed
N
ot
de
sc
rib
ed
Li
eb
er
-d
eC
ar
li
di
et
-f
ed
S
pr
ag
ue
–
D
aw
le
y
ra
ts
67
D
ie
ta
ry
Li
qu
id
hi
gh
-f
at
di
et
N
o
N
ot
ob
es
e
Ye
s
↑In
su
lin
N
ot
de
sc
rib
ed
N
ot
de
sc
rib
ed
Ye
s
Ye
s
M
ito
ch
on
dr
ia
li
nj
ur
y
N
or
m
al
A
LT
N
ot
de
sc
rib
ed
A
po
,
ap
ol
ip
op
ro
te
in
;
FF
A
,
fr
ee
fa
tt
y
ac
id
s;
TN
F,
tu
m
or
ne
cr
os
is
fa
ct
or
.
CZ Larter and MM Yeh Animal models of steatohepatitis
7Journal of Gastroenterology and Hepatology (2008) © 2008 The Authors
Journal compilation © 2008 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd
1
2
3
4
5
6
7
8
9
10
11
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
JOBNAME: No Job Name PAGE: 8 SESS: 9 OUTPUT: Tue Jul 15 12:48:46 2008 SUM: A624CDDF
/v2503/blackwell/journals/jgh_v23_i8/jgh_5543
concomitant reduction in dietary vitamin and mineral content to a
level below that consumed by control animals. Therefore, the
effects of protein, vitamin and mineral restriction need to be con-
sidered in the interpretation of this model. A tentative conclusion is
that this model, like the MCD dietary model, has striking histo-
logical similarities to human NASH. However, the failure of the
model to recapitulate the metabolic milieu (obesity, insulin resis-
tance, glucose intolerance, metabolic syndrome) could limit its
applicability for steatohepatitis research directed at disease patho-
genesis and therapeutic intervention.
Overnutrition as a model of
steatohepatitis
Overnutrition, which is chronic energy intake surfeit to the daily
energy requirements of the individual, is a central feature of the
‘modern lifestyle’ that predisposes to overweight and obesity,
insulin resistance and fatty liver disease. It follows that animal
models which use caloric overload as the main abnormality to
drive liver injury are conceptually desirable for their similarity to
the human condition. High-fat feeding has been used to induce
overnutrition. However, a common problem is that rodents may
adapt to high-fat feeding and become resistant to the development
of obesity, and/or other metabolic abnormalities.65 Researchers
have attempted to overcome this self-correcting mechanism in two
ways; first, through the use of forced feeding via gavage,
implanted gastrostomy tube or total enteral nutrition and, second,
by using animals which exhibit hyperphagia by virtue of appetite
dysregulation.
Overnutrition induced by high-fat diet
The effects of giving a high-fat diet to rodents can be highly
variable. Some studies show clear induction of steatosis and ste-
atohepatitis, whereas others show very few, if any, liver abnormali-
ties. Some of this variability could be explained by the influence of
rodent strain which is known to be important in the susceptibility
to several forms of liver disease. In a recent longitudinal study,
chronic administration of a high-fat diet (60% of calories from fat)
led to the development of steatohepatitis in male C57Bl/6J mice.66
After 10 weeks of feeding, high-fat-fed animals were heavier, with
raised plasma insulin, total cholesterol and hepatic triglyceride
levels, and mice showed impaired glucose tolerance. Hepatic trig-
lyceride content was further increased at 19 weeks, and remained
elevated throughout the study. Serum ALT and AST levels were
increased after 34 weeks of high-fat feeding, but histological data
were only provided for mice fed for 50 weeks. At this time,
high-fat feeding had induced marked steatosis accompanied by
inflammatory infiltrate. Azan stain showed mild fibrosis but with a
perivenular and pericellular pattern. In summary, NASH develops
in high-fat-fed C57Bl/6J mice, and is linked to similar pathogenic
factors as in humans, with steatosis and metabolic syndrome pre-
ceding the transition to steatohepatitis (Table 3). However, if a
50-week feeding period is required for the development of histo-
logical steatohepatitis, the practicality of this model is limited by
the length of feeding required.
In rats, Sprague–Dawley animals appear susceptible to steato-
hepatitis development when fed a high-fat diet, and this is likely
associated with their susceptibility to diet-induced obesity. A
highly cited study by Lieber and colleagues described the effects
of feeding a liquid high-fat diet, the Lieber-DeCarli diet, to
Sprague–Dawley rats.67 In this study, 3-weeks ad libitum high-fat
feeding induced steatosis and inflammation. The pathology was
attenuated by restricting dietary intake. By ultrastructural analy-
ses, high-fat-fed rats also showed more extensive mitochondrial
abnormalities, including rarefied matrix, loss of cristae, and her-
niation. While mitochondrial dysfunction produces reactive
oxygen species that can provoke an array of responses to result in
hepatocyte injury and cell death, inflammation, and fibrosis, it is
not certain whether the abnormal mitochondrial morphology
viewed by electron microscopy represents the cause or result of the
observed histopathology. It is also unclear whether significant
fibrosis developed in this model (Table 2). Interestingly, despite
clear histomorphological abnormalities, there were no biochemi-
cal markers of liver injury, and, in particular, serum ALT and AST
levels remained similar to controls. During ad libitum feeding, a
similar caloric intake was observed between high-fat and control-
fed rats, and there was no difference in final bodyweights.
However, there was an approximately twofold increase in serum
insulin levels in high-fat-fed rats, suggesting the presence of
insulin resistance in this model. Overall, this model does not
convincingly recapitulate the full spectrum of liver pathology, or
the metabolic context of human NAFLD/NASH.
In another study examining the effects of high-fat-feeding on
Sprague–Dawley rats, animals were fed a solid high-fat diet for up
to 6 months.68 In this study, chronic caloric overconsumption was
achieved in high-fat-fed rats and this was accompanied by
increased weight gain and visceral adiposity. In comparison to
low-fat-fed controls, serum glucose and insulin levels were
elevated after 1 month of high-fat feeding and remained elevated
throughout the 6-month study period; hyperglycemia became
more exaggerated with time. A time-dependent increase in portal
serum free fatty acids (FFA) was also observed, as were increased
serum TNF-a and decreased serum adiponectin levels. Analyses of
insulin receptor substrate, (IRS)1, demonstrated increased serine
phosphorylation, which inhibits the pathway of tyrosine phospho-
rylation. This signaling abnormality provided further evidence of
hepatic insulin resistance in this model. Histologically, the rats fed
with a solid high-fat diet developed predominantly macrovesicular
steatosis in the liver. The distribution of steatosis was zone 3 and
zone 1 by the first month, but became more generalized by 3 and
6 months. Scattered lobular inflammatory infiltrates were evident
in zone 3 after 1 month of dietary feeding, and became more
extensive by 3 and 6 months. These inflammatory infiltrates con-
tained not only polymorphs, but also foci of mixed inflammatory
cells, together with hepatocytic necrosis and apoptosis throughout
the hepatic lobule. These observations correlated with the
increased levels of hepatic TNF-a, expressed at both the mRNA
and protein levels. In addition, zone 3 pericellular and perisinu-
soidal fibrosis was observed (Table 3).
Giving n-3 polyunsaturated fatty acids, which are natural
PPARa ligands, to these animals reduced both hepatic steatosis
and necroinflammation scores, and also the number of apoptotic
bodies. These findings were accompanied by a decline in both
hepatic TNF-a mRNA and serum ALT levels. In summary, this
high-fat-feeding model appears to recapitulate many of the
metabolic features of human NASH, as well as developing liver
Animal models of steatohepatitis CZ Larter and MM Yeh
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histology that appears to mimic human NASH pathology, includ-
ing steatosis, inflammation, and liver cell injury.
Despite the above findings, chronic administration of a high-fat
diet to rodents does not always ensure development of steatohepa-
titis. In a study of Wistar rats, feeding high saturated-fat diets for
up to 14 weeks caused no abnormalities in liver histology, and few
aberrations in the metabolic health of these rodents.65 High-fat
feeding was associated with increased caloric intake, but minimal
or no increase in bodyweight. Adipose mass and adipocyte size
increased in high-fat-fed rats, but this apparent partitioning of
triglyceride into adipose prevented hepatic triglyceride accumula-
tion. Another adaptation to high-fat feeding was observed in the
brown adipose tissue, which showed a modest expansion and
increase in expression of uncoupling protein. The latter indicates
increased thermogenesis, which may counter the effects of
increased caloric intake in high-fat-fed Wistar rats. Thus, although
some high-fat-feeding models appear well suited for NASH
research, the challenge to reproduce them reliably between differ-
ent laboratories may limit their utility and popularity.
Intragastric overnutrition
A number of models have now been described in which caloric
overload is deliberately given to rodents. The pioneering study was
in 2005 by Deng and colleagues, who described a gastric overnu-
trition model that delivered a caloric intake up to 185% that of
normal mice through an implanted gastrostomy tube.69 The
feeding emulsion consisted of 37% of calories from fat (corn oil)
and 39% as dextrose. In control mice fitted with an intragastric
feeding device, but fed equivalent to normal caloric intake, weight
gain was similar to that reported with ad libitum feeding. In con-
trast, over-fed mice developed severe obesity that was associated
with increases in fasting serum glucose and insulin levels, and
impaired insulin sensitivity. In adipose tissue, leptin mRNA
increased in association with serum leptin levels, whereas adi-
ponectin mRNA levels fell. Adipocyte TNF-a mRNA levels were
increased, but overfeeding in TNF-a receptor-1 null mice demon-
strated TNF-a signaling was not required for steatohepatitis
development. All mice in the overfeeding group developed
hepatomegaly associated with steatosis and increased serum ALT.
Approximately half (six of 13 mice) went on to develop steato-
hepatitis. Steatosis was induced in most hepatocytes. The hepatic
parenchyma was notable for aggregates of inflammatory cells,
predominantly neutrophils and surrounding hepatocytes that
showed microvesicular steatosis. Whereas human NASH histol-
ogy is typically characterized by macrovesicular steatosis, and
neutrophilic aggregates are not common (instead they are more
often seen in alcoholic hepatitis), the histological injury in this
model correlated with elevated serum ALT levels. As demonstrated
by reticulin stain, there was also perisinusoidal and pericellular
fibrosis, resembling the typical fibrosis pattern seen in human
NASH. The gastric overnutrition model has many advantages
(Table 3). First, transition to steatohepatitis appears to be sponta-
neous. Second, it occurs in the context of obesity, insulin resis-
tance and metabolic syndrome. Third, the liver histology mimics
human NASH. However, a 10–15% mortality rate and the require-
ment for technical expertise (or expensive purchasing from an
experimental facility) may prevent this model from becoming a
readily available tool for studying steatohepatitis development.
A similar model has recently been described in rats. Modest
caloric overload is given via an intragastric cannula. In this study,
rats given a 5% fat (as energy) diet that was 17% in excess of
caloric requirement for 21 days became obese; there was increased
adiposity as well as increased serum leptin and blood glucose
levels.70 Comparable caloric overload, but with dietary fat content
increased to 70% fat (as energy), caused similar metabolic pertur-
bations, but was also associated with decreased serum adiponectin
levels, increased serum triglyceride, FFA and ALT levels, as well
as histological evidence of steatohepatitis. Whereas overfeeding
with regular diet alone was not associated with significant liver
pathology, overfeeding with increased dietary fat content caused a
dose-dependent increase in macro- and microvesicular steatosis,
and lobular inflammation. These findings were accompanied by
elevated serum ALT levels. When overfed rats were studied to 65
days, there was a further increase in serum ALT and evidence of
hepatic fibrosis in the portal/periportal and lobular regions, sug-
gesting progressive liver injury. In this model, ballooning degen-
eration of the hepatocytes was described, but the score was not
significantly different between high- and low-dietary fat groups,
and photomicrographs of ballooned hepatocytes were not pre-
sented in the article. Another feature of this model is that rats are
sedentary. Previous studies indicated that activity levels were
reduced by approximately 50% as rats do not expend energy to eat.
Although this model successfully recapitulates the metabolic
context of human NASH, at 21 days the extent of liver injury and
inflammation and hepatic triglyceride content is only modest
(Table 3). Fibrosis is evident at the later time-point (65 days), but
the omission of histological scores for inflammation and balloon-
ing degeneration at this time-point prevent critical assessment of
this model at this stage of development.
Another approach to overnutrition was described by Zou and
colleagues in 2006.71 In their study, rats were allowed ad libitum
access to food, water and an 18% saccharose solution. To induce
caloric overload, rats were then given daily, by gavage, 10 mL/kg
of a high-fat, high-cholesterol emulsion, whereas controls were
given saline. After 6 weeks of overfeeding, rats given the high-fat
emulsion had gained more weight, had increased blood glucose,
insulin, triglyceride, total cholesterol, LDL–cholesterol, FFA and
TNF-a levels, whereas HDL–cholesterol levels were decreased.
Serum ALT levels were elevated and liver histology demonstrated
significant steatosis, predominantly macrovesicular, and an
inflammatory cell infiltrate. However, biochemical measures of
lipid accumulation demonstrated only modest triglyceride accu-
mulation (~1.5-fold), as well as increased total cholesterol (~five-
fold) and free fatty acids (~threefold). Ultrastructurally, the
hepatocytes showed aberrant mitochondria, including mitochon-
drial swelling, rarefied matrix, and loss of cristae. Similar ultra-
structural changes in mitochondria have been described in human
NASH, and may reflect injury or adaptive changes.72,73 Although
not specifically described, under light microscopy, these changes
are suggested to reflect the megamitochondria seen in human
NASH; megamitochondria are round or needle-shaped intracyto-
plasmic inclusions.11,15,16 Pericentral hepatocytic necrosis was also
observed in this study. However, typical liver cell injury and
sequelae seen in human NASH, such as hepatocytic ballooning
and fibrosis, were not described. A more thorough description of
the liver pathology is required before the utility of this model can
be fully assessed (Table 3). However, as the model requires daily
Animal models of steatohepatitis CZ Larter and MM Yeh
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gavage of the lipid emulsion for 6 weeks (possibly longer to induce
fibrosis), it is clearly labor intensive and the practicality of such a
model will likely limit its use in steatohepatitis research.
Hyperphagia-driven overnutrition
Caloric overconsumption is thought to be one of the main under-
lying causes of the obesity epidemic.74 Therefore, animal models
of steatohepatitis in which hyperphagia is a central feature are
attractive for their similarity to humans. Genetically obese animals
such as ob/ob and db/db do not readily develop steatohepatitis, as
discussed earlier. However, the Zucker fatty rat (fa/fa), which has
a defect in the leptin receptor, does develop steatohepatitis when
given a high-saturated-fat diet. After 8 weeks of high-fat feeding,
fa/fa rats were obese with fasting hyperglycemia. They exhibited
elevated serum ALT levels, which correlated with histological liver
injury.75 In contrast, high-fat-fed controls developed only mild
steatosis, as did low-fat-fed fa/fa rats which were also obese but
showed only mild fasting hyperglycemia and minor ALT elevation.
In high-fat-fed fa/fa rats with steatohepatitis, the distribution of
steatosis began in the periportal region and extended to the lobules
and central region. Fibrosis was also accentuated in the portal
region. Thus, the lobular pattern of steatosis, liver injury and
deposition of collagen in this model seem different from that seen
in human adults with NASH, which show injury and fibrosis
initially in zone 3. Ballooning degeneration of the hepatocytes was
also described in this brief report, but it was not shown in the
figures. In summary, high-fat-fed fa/fa rats appear to exhibit most
metabolic and histological features similar to human NASH
(Table 3). However, a more thorough description of the metabolic
phenotype, for example, serum adipokine levels, as well as more
extensive illustration of hepatic pathology, including images of
ballooned hepatocytes, would enable the utility of this model to be
established.
Another model of hyperphagic obesity is the foz/foz mouse.
These animals have a spontaneous, truncating mutation in Alms1,
the gene responsible for Alström syndrome in humans. Chow-fed
foz/foz mice consume approximately 30% more calories than their
wild-type littermates, are obese with increased adiposity, hyperc-
holesterolemia, insulin resistance and glucose intolerance; diabe-
tes develops by approximately 4 months of age.76 High-fat feeding
exacerbates this phenotype, and a striking reduction in serum
adiponectin levels occurs. This appears to be associated with the
spontaneous transition from the simple steatosis as observed in
chow-fed foz/foz mice (and wild-type high-fat-fed mice) to severe
steatohepatitis (Fig. 1).77 Histologically, foz/foz mice fed a high-fat
diet for approximately 300 days show mixed microvesicular and
macrovesicular (predominantly macrovesicular) steatosis, and also
ballooning degeneration of hepatocytes (Fig. 1c) with multiple
foci of inflammatory cells (neutrophils and mononuclear cells) in
hepatic lobules (Fig. 1d). Perivenular and pericellular (chicken-
wire) fibrosis is also present in foz/foz mice with steatohepatitis
(Fig. 1e). Of note, severely affected animals showed architectural
distortion of the liver due to dense fibrosis. We have recently
presented data showing that high fat-fed foz/foz mice develop liver
histology representing steatohepatitis (steatosis, lobular inflamma-
tion, ballooned hepatocytes and fibrosis) as early as 6 months.78 In
fact, metabolic abnormalities and serum ALT elevation have been
observed from as early as 6 weeks of high-fat feeding (C Larter &
G Farrell, unpubl. data, 2008). Thus, the phenotype of high-fat-fed
foz/foz mice appears to recapitulate the liver pathology that defines
human NASH, in the context of multiple features of the metabolic
milieu in which steatohepatitis develops (Table 3). Specifically,
mice are obese with increased adiposity, insulin resistance, hyper-
glycemia, hyperinsulinemia, high serum leptin levels and low
serum adiponectin levels.
Summary and conclusion
A number of rodent models of steatohepatitis have recently been
described. Some recapitulate the liver injury observed in human
NASH, but in a different metabolic context (nutritional deficien-
cies, or insulin sensitivity) (Table 1), whereas others develop in the
metabolic context of NAFLD but without full development of
steatohepatitis (Table 2). More recently, models of overnutrition
have been achieved through high-fat feeding, forced caloric over-
load or studying genetically hyperphagic mice fed a high-fat diet
(Table 3). These models appear most suited to studying the
complex biological interactions that are involved in the develop-
ment of fatty liver disease. In particular, these models enable
steatohepatitis researchers to assess the contribution of the meta-
bolic milieu of insulin resistance, obesity, dyslipidemia, altered
adipokine and cytokine profile, as well as oxidant stress to the
development of liver injury. The mechanisms of hepatocellular
injury, inflammatory recruitment, fibrosis and carcinogenesis can
appropriately be studied in such models.
We trust that the need for a thorough description of new animal
models is evident from this review. It must be emphasized that
comprehensive information on both liver pathology and metabolic
phenotype should be included when new models are described.
From the metabolic viewpoint, markers of obesity (weight gain,
adipose mass), body fat distribution, insulin resistance (blood
glucose and insulin levels, and or dynamic measures of insulin
sensitivity), serum lipids and adipokine profile (serum adiponec-
tin, leptin, TNF-a and IL-6 levels), provide valuable information
for judging the value of models in terms of their metabolic simi-
larities to human NASH.
Comparative studies of liver pathology between models, as well
as within models at different stages of their evolution, would be a
valuable contribution to knowledge in this area. Agreement on
what comprises steatohepatitis in experimental models is urgently
required if we are to reliably interpret studies that use established
models to investigate pathogenesis or therapeutic pathways. For
example, the sum of scores for steatosis, lobular inflammation, and
hepatocellular ballooning was used to generate a NAFLD activity
score (NAS) proposed by the NIDDK sponsored NASH Clinical
Research Network (CRN). NAS has been widely used for clinical
trials in patients since its validation. We have also adopted this
scoring system in experimental animals such as MCD mice and the
foz/foz model (C Larter et al., unpubl. data, 2008). In both models,
we have found good correlation between the NAS and serum ALT
levels.79,80 However, lack of agreement on the validity of this or
other approaches currently hampers laboratory-based NASH
research.
In conclusion, in order to determine pathogenic mechanisms of
liver injury and, particularly, what causes the transition from ste-
atosis to steatohepatitis, appropriate animal models are required.
As NASH appears to be a slowly evolving form of liver pathology
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in humans, models of chronic overnutrition with spontaneous pro-
gression of steatosis to steatohepatitis may be the most valid and
practical means to study the complex interplay between metabolic
abnormalities and liver injury. The ‘two-hit hypothesis’, which
usefully emphasized that mechanisms of liver injury and inflam-
matory recruitment may not be directly related to those for lipid
accumulation (steatosis),81 may be an oversimplification of steato-
hepatitis pathogenesis. A more realistic conceptual basis for
NASH is that cumulative small pathogenic steps (‘hits’), such as
overnutrition, underactivity and insulin resistance on the back-
ground of genetic susceptibility initiate the transition of steatosis
to NASH. It is critical that as more animal models become avail-
able these reflect this pattern of disease development. In the mean-
time, we believe that developments since 2005 place the field
where preference should be given to ‘metabolic models’ that show
appropriate pathology over models with parallel pathology, but
created by non-physiological metabolic pathways or nutrient defi-
ciency. In 2009, it is time for NASH researchers to look beyond the
MCD model.
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